{"links":{"feed":"https://www.erudio.com/reports/rosetta-crc-203-nct07221357/feed.json","html":"https://www.erudio.com/reports/rosetta-crc-203-nct07221357","json":"https://www.erudio.com/reports/rosetta-crc-203-nct07221357.json","markdown":"https://www.erudio.com/reports/rosetta-crc-203-nct07221357.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"rosetta-crc-203-nct07221357"}},"request":"https://www.erudio.com/contact?report=rosetta-crc-203-nct07221357"},"offer":{"cited_clinicians":1,"cited_commentary_sources":5,"verified_hcp_statements":7,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":1},"for_sale":false,"one_off_usd":null,"not_for_sale":{"note":"This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested. No order can be placed for it; a later edition that reaches the minimum is for sale at its normal price.","contact":"https://www.erudio.com/contact?report=rosetta-crc-203-nct07221357","email":"hello@erudio.com"},"purchase":{"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=rosetta-crc-203-nct07221357","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/rosetta-crc-203-nct07221357","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 7 verified statements · 7 from 1 confirmed clinician","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":null,"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-16T22:31:32.882311Z","notify_subscribers":false,"status":"corrected","summary":"taxonomy mapping corrected"},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":6,"no_commentary_found":5},"aspects":[{"claim_count":0,"coverage":"no_commentary_found","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":0,"title":"Primary endpoint: Objective Response (OR) (confirmed complete response (CR) or partial response (PR)) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator assessment"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":0,"title":"Primary endpoint: Progression Free Survival (PFS) by RECIST v1.1 per blinded independent central review (BICR)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T3","registry_field":"outcomesModule.primaryOutcomes[2]","source_count":0,"title":"Primary endpoint: Overall Survival (OS)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T4","registry_field":"outcomesModule.secondaryOutcomes","source_count":0,"title":"Secondary endpoints"},{"claim_count":4,"coverage":"discussed","id":"T5","registry_field":"conditionsModule","source_count":3,"title":"Population and setting"},{"claim_count":2,"coverage":"discussed","id":"T6","registry_field":"armsInterventionsModule.armGroups","source_count":2,"title":"The comparison"},{"claim_count":0,"coverage":"no_commentary_found","id":"T7","registry_field":"armsInterventionsModule.interventions","source_count":0,"title":"Safety and tolerability"},{"claim_count":2,"coverage":"discussed","id":"T8","registry_field":"designModule","source_count":2,"title":"Design and conduct"},{"claim_count":3,"coverage":"discussed","id":"A1","source_count":3,"title":"Expected clinical impact"},{"claim_count":3,"coverage":"discussed","id":"A2","source_count":3,"title":"Trial access, referral and geographic expansion"},{"claim_count":2,"coverage":"discussed","id":"A3","source_count":1,"title":"Future bispecific treatment positioning"}],"counts":{"beyond_population_findings":1,"beyond_population_statements":2,"cited_clinicians":1,"cited_clinicians_by_role":{"physician":1},"cited_physicians":1,"cited_sources":5,"claims_by_expression_type":{"experience":2,"opinion":4,"restatement":1},"claims_by_kind":{"source_observation":7},"clinician_statements":7,"evidence_units":9,"findings":3,"people_cited":1,"people_identity_verified":1,"people_total":1,"screened_sources":10,"verified_claims":7},"findings_index":[{"cited_clinicians":1,"id":"F1","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":3},"limitations":2,"links":{"context":0,"support":3},"ma_question":true,"named_voices":1,"passages":3,"sources":3,"sources_by_kind":{"commentary":3}},"title":"ROSETTA in colorectal cancer: why a clinician sees potential to change care","title_holders":{"cited_claim_ids":["claim-f03709650873f1faf5ca","claim-cb232dc1e0a7d4cc4fbc"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"3 statements from 1 speaker in 3 sources","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician"},{"cited_clinicians":1,"id":"F2","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":1,"views":1},"limitations":2,"links":{"context":0,"support":4},"ma_question":true,"named_voices":1,"passages":3,"sources":3,"sources_by_kind":{"commentary":3}},"title":"ROSETTA access: a clinician notes an open site and discusses Latin American expansion","title_holders":{"cited_claim_ids":["claim-0f5047f1c0f09f2c5777","claim-c8426337a3d3bef781ca","claim-cb232dc1e0a7d4cc4fbc"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"3 statements from 1 speaker in 3 sources","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician"},{"cited_clinicians":1,"id":"F3","population":"beyond","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":0,"views":1},"limitations":2,"links":{"context":0,"support":2},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Anti-VEGF vs EGFR: a clinician sees a possible future rerun with bispecifics","title_holders":{"cited_claim_ids":["claim-6ca7f8b5d5a8d2234b3d"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"2 statements from 1 speaker in 1 source","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician"}],"open_question":{"reason":"No question clinicians left open passed this edition's checks and review.","status":"unavailable"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"One X account sees potential for ROSETTA to change first-line care"},{"id":"section-2","level":2,"title":"One X account distinguishes reported Moffitt access from expansion discussions"},{"id":"section-3","level":2,"title":"Beyond the trial population"},{"id":"section-4","level":3,"title":"One X account anticipates a future bispecific treatment-selection debate"},{"id":"section-5","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase2, phase3","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Objective Response (OR) (confirmed complete response (CR) or partial response (PR)) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator assessment"},{"findings":[],"id":"T2","label":"Primary endpoint: Progression Free Survival (PFS) by RECIST v1.1 per blinded independent central review (BICR)"},{"findings":[],"id":"T3","label":"Primary endpoint: Overall Survival (OS)"},{"findings":[],"id":"T4","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1}],"id":"T5","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1}],"id":"T6","label":"The comparison"},{"findings":[],"id":"T7","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":1}],"id":"T8","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-16T22:31:32.882311Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-17T21:15:11Z","record_hash":"2a2ed6cd7557f7fb916a779f07c71c62a9442e94c01e8a955298e25151eb2967","release_hash":"a4d0a35a78151783e42701a39b401474e2e5fb18fa1277435dc5ed0790f8147d","report_id":"erudio-nct07221357","run_id":"5f399fbf-e317-41cc-9312-9fdc6d5a4757","schema_version":"5.0","slug":"rosetta-crc-203-nct07221357","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"A physician described in the sources as serving on the ROSETTA CRC-203 steering committee sees scope for treatment change, reflecting expectations for bispecifics rather than reported benefit. They offered a referral route, but additional Latin American sites were only being discussed. Their forecast about anti-VEGF versus EGFR choices concerns future bispecific development, not evidence favoring either strategy. The statements do not assess benefit or safety or establish wider clinical agreement.","examples":[],"meta_description":"10 sources screened · 7 verified statements (7 from clinicians verified by NPI or staff page) from 5 sources · 3 findings. Updated Nov 16, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-17T21:15:11Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-11-18T05:59:40Z","kind":"routine","summary":"taxonomy mapping corrected"}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":10},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","2 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 39 sources about other trials or topics are not included.","The substantive views come from one X author, described in the sources as on the ROSETTA CRC-203 steering committee. Multiple posts and reposts do not establish independent endorsement or wider HCP agreement.","Discussion that does not explicitly name the trial, or uses other naming variants, may be missing, limiting conclusions about the breadth of HCP opinion.","No exact-trial publication or full protocol was identified for this edition. The cited statements do not evaluate response, progression-free survival, overall survival, safety or detailed patient selection.","Site-access statements describe the circumstances reported on the post dates. Proposed Latin American expansion should not be read as confirmation that additional centers opened."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":5,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":5},"count":5,"evidence_window":{"end":"2026-05-15","start":"2026-02-27"},"retrieval_snapshot":"2026-11-16T22:21:16.132131Z","timeline":[{"count":1,"week":"2026-W09"},{"count":1,"week":"2026-W14"},{"count":1,"week":"2026-W17"},{"count":2,"week":"2026-W20"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT07221357:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT07221357:context","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-tsqfr6zfxr7jcxoceowmozu4-3mufibr6i3d2i","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1986047938825687387:e0183473-a76c-470f-b524-64faec344475","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1986407051606827346:5d271c87-1d8f-41a8-a76e-1464add4a54c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2027482934718996619:0e789bc7-f130-4543-8ecc-ea5d3f6c4add","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2039091356916678923:b3134480-3a56-4d4c-8920-9a184ecfa076","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2047170644320583776:1bfaa508-aa69-496c-89cc-e4e6455b4fed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2055369811799220700:06c28f92-059c-4dca-a587-bfcee2976673","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2055373909898534943:ab9712cd-c37d-404c-85c1-ebb4cf961e62","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060360514136354838:bd620445-5523-4e0b-a591-ab903b7e8e79","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2072311762913820905:7ff5d431-aec2-4de4-9322-d60212fdeaa2","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":9,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":10},"count":10,"evidence_window":{"end":"2026-08-31","start":"2025-11-05"},"retrieval_snapshot":"2026-11-16T22:21:16.290666Z","timeline":[{"count":2,"week":"2025-W45"},{"count":1,"week":"2026-W09"},{"count":1,"week":"2026-W14"},{"count":1,"week":"2026-W17"},{"count":2,"week":"2026-W20"},{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W27"},{"count":1,"week":"2026-W36"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":7,"x_video":0,"youtube":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"pumitamig","slug":"pumitamig"},{"brand_names":["Vykoura","Wellcovorin"],"label":"leucovorin","slug":"leucovorin"},{"brand_names":["Adrucil","Favlyxa"],"label":"fluorouracil","slug":"fluorouracil"},{"brand_names":["Eloxatin"],"label":"oxaliplatin","slug":"oxaliplatin"},{"brand_names":["Camptosar"],"label":"irinotecan","slug":"irinotecan"},{"brand_names":["Avastin"],"label":"bevacizumab","slug":"bevacizumab"},{"brand_names":["Xeloda"],"label":"capecitabine","slug":"capecitabine"}],"indications":[{"reason":"Unmapped registry condition: Untreated, Unresectable, or Metastatic Colorectal Cancer","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Colorectal cancer","slug":"colorectal-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"ROSETTA CRC-203","aliases":["ROSETTA CRC-203","CA266-0003","A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer","ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer"],"brief_title":"A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer","collaborators":["BioNTech SE"],"conditions":["Untreated, Unresectable, or Metastatic Colorectal Cancer"],"display_condition":"previously untreated, unresectable or metastatic colorectal cancer","display_interventions":[["pumitamig"]],"enrollment":{"count":990,"type":"ESTIMATED"},"interventions":[{"name":"Pumitamig","synonyms":["BMS-986545","BNT327","PM8002"],"type":"DRUG"},{"name":"FOLFOX","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"FOLFIRI","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Bevacizumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"CAPOX","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT07221357","official_title":"ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer","overall_status":"RECRUITING","phase":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2030-02-02","type":"ESTIMATED"},"primary_endpoints":[{"description":"Phase 2","measure":"Objective Response (OR) (confirmed complete response (CR) or partial response (PR)) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator assessment","timeFrame":"Up to 5 years"},{"description":"Phase 3","measure":"Progression Free Survival (PFS) by RECIST v1.1 per blinded independent central review (BICR)","timeFrame":"Up to 5 years"},{"description":"Phase 3","measure":"Overall Survival (OS)","timeFrame":"Up to 5 years"}],"registered_date":{"date":"2025-10-27","type":"ACTUAL"},"registry_last_updated":"2026-10-23","registry_url":"https://clinicaltrials.gov/study/NCT07221357","short_name":"ROSETTA CRC-203","short_name_basis":"canonical_name","sponsor":"Bristol-Myers Squibb","start_date":{"date":"2025-12-31","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase2, phase3","study_ids":[{"id":"CA266-0003","type":"sponsor_study_id"},{"domain":"EU CT Number","id":"2025-523224-45","type":"other"},{"domain":"UTN","id":"U1111-1325-6505","type":"other"}],"study_type":"INTERVENTIONAL"}}}